Specifications TableSubject area*Biochemical Genetics*More specific subject area*Inborn Errors of Metabolism*Type of data*Table*How data was acquired*Tecan Fluorometer Infinite M200 (2010), High resolution of electrophoresis*Data format*Raw, Analysed data*Experimental factors*Selective screening among high risk patients of mucopolysaccharidoses (MPS) in Malaysia based on inclusion criteria*Experimental features*Urine and blood from patients with high risk symptoms of mucopolysaccharidoses were analysed using test method. Demographic data and obtained results were analysed*Data source location*Kuala Lumpur, Malaysia*Data accessibility*The dataset is accessible within this article data*Related research article*Affandi Omar,* Julaina A.Jalil*,* Norashareena M.Shakrin*,* Lock H.Ngu*,* Zabedah M.Yunus*. Selective screening for detection of mucopolysaccharidoses in Malaysia; A two-year study (2014--2016). Molecular Genetics and Metabolism Reports 19 (2019) 100469***Value of the data**•The dataset in this article will help further research on inborn error of metabolism in Malaysia. Policy maker, researchers and other stakeholders can use the dataset to compare the findings whether to include the commonest type of MPS in LSD newborn screening in future.•The dataset provides demographic data of patients with high risk of mucopolysaccharidoses•Data in this work provides further understanding of the correlation between clinical presentation and laboratory findings in patients with high risk of MPS.

1. Data {#sec1}
=======

This article presents data from high-risk patients profiling of mucopolysaccharidoses in Malaysia from 2014 to 2016 related to the recent study described by Omar A. [@bib1]. Mucopolysaccharidoses (MPS) is a group of disorders characterised by the accumulation of glycosaminosglycans (GAGs) in tissues and organs due to defects in specific enzymes contained within lysosomes. Chondroitin sulphate (CS), dermatan sulphate (DS), heparan sulphate (HS), keratin sulphate (KS) and hyaluronic acid (HA) are subtype sulphated polyssacharides of GAGs [@bib12]. MPS, like other type of inherited metabolic disorders, is still remains under diagnosed by physician due to its rareness and complexity of symptom presentation [@bib8].

[Table 1](#tbl1){ref-type="table"} summarizes the demographic data of 58 patients included in this selective screening. This data is useful to understand the pattern of these patients as some of the patients showed prominent symptom of MPS however was found to be negative during screening and confirmation. Hepatomegaly and dysmorphic features are the most common symptoms among high risk patients during the study period. Clinicians and physicians would find this data useful for them to investigate any suspected MPS patients in future.Table 1High risk patients profiling of selective screening for mucopolysaccharidoses (MPS) in Malaysia (2014--2016).Table 1NoRegionAge (Year)SymptomGAGs value (mmol/g creat)GAGs level (based on age)HRE bandDiagnosis1Northern1.42Hepatomegaly, Dysmorphic53.3AbnormalTrace amount of DS band.Normal2East Coast2.00Hepatomegaly, dysmorphic35.34AbnormalNormal patternNormal3Northern5.08Dysmorphic, achondroplasia15.27AbnormalTrace amount of HS bandNormal4Sarawak6.00Pectus carinatum, short stature13.76NormalNormal pattern.Normal5Sarawak2.00Pectus carinatum, short stature18.55NormalNormal pattern.Normal6Northern5.00Hepatomegaly, Dysmorphic19.72AbnormalNormal pattern.Normal7Northern1.42Hepatomegaly, Splenomegaly34.97AbnormalNormal pattern.Normal8Northern56.00Dysmorphic, short stature6.86NormalNormal pattern.Normal9Northern16.00Dysmorphic, short stature, kyphosis5.36NormalTrace amount of HS bandNormal10East Coast1.83Dysmorphic, hepatosplenomegaly28.02AbnormalTrace amount of HS bandNormal11Southern9.00Dysmorphic, Clawed hand, kyphoscoliosis10.35NormalNormal patternNormal12Northern0.25Hepatomegaly, umbilical hernia44.08AbnormalNormal patternNormal13East Coast0.05Dysmorphic76.33AbnormalIncrease of HS bandNormal14East Coast4.92Dysmorphic1.84NormalIncrease HS bandNormal15Sabah2.25Hepatomegaly, Dysmorphic18.51NormalNormal patternNormal16East Coast14.00Eye lesions, dysmorphic7.49NormalTrace amount of HSNormal17Central8.00Joint contracture11.89NormalNormal patternNormal18Sarawak3.00Hepatomegaly, Dysmorphic9.61NormalTrace amount of HS bandNormal19Northern0.17Hepatomegaly, Dysmorphic44.82AbnormalNormal pattern.Normal20Central4.00Dysmorphic18.54NormalNormal pattern.Normal21Central0.33Hepatomegaly, Dysmorphic34.82AbnormalNormal patternNormal22Central0.50Hepatomegaly, Dysmorphic47.98AbnormalNormal patternNormal23Southern12.06Hepatomegaly, Dysmorphic10.35NormalTrace amount of HS bandNormal24Central4.00Hepatomegaly, Dysmorphic8.28NormalNormal patternNormal25Sabah1.25Dysmorphic, hepatosplenomegaly16.72NormalNormal patternNormal26Central2.00Dysmorphic, hepatosplenomegaly15.95NormalTrace amount of HS bandNormal27Northern0.67Dysmorphic, hepatosplenomegaly42.36AbnormalNormal patternNormal28Southern7.42Dysmorphic, genu valgum/bowing legs11.76NormalMarked increase in CS bandNormal29Northern7.00Kyphoscoliosis92.82AbnormalPresence of HS bandNormal30Northern10.00Dysmorphic, hepatosplenomegaly13.33AbnormalPresence of mild HS bandNormal31Northern0.33Hepatosplenomegaly, respiratory distress29.91NormalIncrease of CS band with presence of mild HS bandNormal32Northern0.33Corneal clouding43.02AbnormalMild increase of DS band and trace amount of HS bandNormal33Southern6.00Dysmorphic7.93NormalPresence of trace amount of HS and DS bandNormal34Northern14.00Dysmorphic, short stature, kyphosis3.81NormalMild increase of HS bandNormal35Southern0.02Dysmorphic40.92AbnormalTrace amount of HS bandNormal36Sabah15.00Dysmorphic, hepatosplenomegaly53.41AbnormalMarked increase of HS bandNormal37Southern11.42Dysmorphic, Clawed hand6.65NormalIncrease of DS band and trace amount of HS bandNormal38Sabah3.00Dysmorphic, hepatosplenomegaly19.7AbnormalPresence of trace HS bandNormal39Sarawak0.16Hepatosplenomegaly, Corneal clouding67.76AbnormalPresence of HS bandNormal40Northern1.58Dysmorphic, gibbus, pectus carinatum56.13AbnormalPresence of KS bandNormal41Central3.00Dysmorphic, respiratory problem108.74AbnormalIncrease of DS band and trace HS bandNormal42Northern0.83Dysmorphic, eye lesions42.86AbnormalPresence of DS band and trace amount of HS bandNormal43Sarawak4.00Dysmorphic76.28AbnormalIncrease of DS and HS bandMPS I44Central0.17asymptomatic (sibling screening)185.35AbnormalIncrease DS and HS bandMPS II45Central1.0Dysmorphic, hepatosplenomegaly----(Result of GAGs screening and HRE characterization were performed in University Hospital)MPS II46Central2.50Dysmorphic, hepatosplenomegaly92.37AbnormalPresence of DS and HS bandMPS II47Central2.00Dysmorphic, Hepatomegaly44.31AbnormalPresence of HS bandMPS IIIA48Central1.58Dysmorphic, Hepatomegaly----(Result of GAGs screening and HRE characterization were performed in University Hospital)MPS IIIA49Central3.12Scoliosis, Claw hand12.44NormalNormal patternMPS IVA50Central7.00Respiratory distress, dysmorphic----HS prominent (Result of GAGs screening were performed in University Hospital)MPS IVA51Central1.08Dysmorphic, Hepatomegaly27.64AbnormalNormal patternMPS VI52Central7.33Dysmorphic, Hepatomegaly69.54AbnormalPresence of DS band with trace amount of HS bandMPS VI53Northern3.25Dysmorphic, corneal clouding51.7AbnormalPresence of DS bandMPS VI54Central0.18Dysmorphic, respiratory problem100.97AbnormalNormal patternMPS VI55Northern2.83Dysmorphic, macrocephaly19.27AbnormalNormal patternMPS VI56Northern2.83Dysmorphic, macrocephaly60.25AbnormalNormal patternMPS VI57Central0.5Dysmorphic, hepatosplenomegaly28.41NormalPresence of HS bandMPS VI58Central0.21Dysmorphic, hepatosplenomegaly39.75AbnormalNormal pattern.MPS VI

[Table 2](#tbl2){ref-type="table"} focuses on demographic data in study population. Male to female ratio is almost proportionate and eliminates gender bias. For ethnicity, we have divided the major races in Malaysia into 6 subcategories: Malay, Chinese, Indian, natives from Sabah and Sarawak region and indigenous people (Orang Asli). We also classified origin hospital of these patients into different regions. For instance, central region comprises any hospital in Federal Territory of Kuala Lumpur and Putrajaya, State of Selangor and State of Negeri Sembilan; northern region (State of Perak, Pulau Pinang, Kedah and Perlis); East Coast region (State of Kelantan, Terengganu and Pahang); Southern (State of Melaka and Johor); Sarawak region and Sabah region. We believe this demographic data would be useful among policy makers to decide whether selective screening should be conducted in selected regions or the whole country.Table 2Demographic data of high risk patients of selective screening for mucopolysaccharidoses (MPS) in Malaysia (2014--2016).Table 2VariablesFrequencyPercentagesGender•Male3153.4•Female2746.6Ethnicity•Malay3662.1•Chinese1627.6•Indian23.4•Sabah Native11.7•Sarawak Native11.7•Indigenous People (Orang Asli)23.4Region•Central1932.8•Northern2034.5•East Coast46.9•Southern610.3•Sarawak58.6•Sabah46.9

[Table 3](#tbl3){ref-type="table"} below describes distribution of GAGs among different age groups in study population. Each age group is carefully divided according to age group in GAGs determination. The data from this table supports the facts that GAGs distribution will be decreased towards increment of age.Table 3Glycosaminoglycans (GAGs) distribution between age group in high risk patients of selective screening for mucopolysaccharidoses (MPS) in Malaysia (2014--2016).Table 3ParametersAge groupLess than 1 year1--4 years4--9 yearsMore than 9 yearsMedian43.0219.1312.837.49Minimum value29.918.281.843.81Maximum value76.33108.7492.8253.41

In general, [Table 4](#tbl4){ref-type="table"} below describes the diagnostic test evaluation for three different approaches in our selective screening of high risk patients of MPS in Malaysia. The first approach was using only GAGs determination using DMB method, the second approach utilised characterization of GAGs using High Resolutions of Electrophoresis (HRE) and the last approach was carried out using a combination of GAGs determination using DMB and GAGs characterization using HRE. The first approach showed high sensitivity but poor specificity while the second approach revealed high specificity but poor sensitivity. By using both analytical methods, we managed to achieve satisfactory performances of sensitivity and specificity (more than 80%). We believe this information will be beneficial to laboratory personnel in order to evaluate their performance and capabilities of current methods.Table 4Diagnostics test evaluation for distinctive approaches of selective screening for MPS in high risk patients in Malaysia (2014--2016).Table 4ParametersGAGsHRECombinationValue95% CIValue95% CIValue95% CISensitivity (%)81.2554.35 to 95.9545.0023.06 to 68.4787.5061.65 to 98.45Specificity (%)47.6232.00 to 63.5881.5865.67 to 92.2683.3368.64 to 93.03Positive predictive value (%)37.1428.94 to 46.1656.2536.01 to 74.666.6749.80 to 80.13Negative predictive value (%)86.9669.61 to 95.1073.8164.84 to 81.1694.5982.62 to 98.47Disease prevalence (%)27.5916.66 to 40.9034.4822.49 to 48.1227.5916.66 to 40.90

In conclusion, demographic data together with clinical symptoms/presentation and laboratory findings are important to assist clinician/researchers for future studies in MPS and can be employed to improve the diagnosis of MPS.

2. Experimental design, materials and methods {#sec2}
=============================================

2.1. Study population and sample collection {#sec2.1}
-------------------------------------------

This is a prospective cross-sectional study involving samples from high-risk children and young adults for MPS conducted over 2 years starting June 2014 to June 2016. A total of 58 urine samples for urinary GAGs quantitation and characterization and whole blood (n = 60) for enzymatic assays were received between 2014 and 2016. Urine samples (20 ml) were kept frozen while whole blood (6 ml) was processed to obtain plasma and leukocytes before stored at −80 °C. All the samples were collected from patients which had least two features of the following of inclusion criteria: (a) abnormal face features such as macrocephaly or coarse face; (b) corneal clouding or loss of visual acuity; (c) hearing impairment and recurrent middle ear infections; (d) recurrent respiratory tract infection; (e) valvular heart disease or heart murmur; (f) recurrent inguinal or umbilical hernia; (g) hepatosplenomegaly; (h) at least two symptom of musculoskeletal: (1) evolving joint contracture without obvious signs of inflammation, (2) joint laxity, (3) gibbus, (4) cervical spine stenosis and/or cord compression, (5) kyphosis or scoliosis, (6) pectus carinatum, (7) bilateral hip dysplasia, (8) progressive genu valgum after age of 3 years old, (9) short stature of unknown reason, (10) carpal tunnel syndrome. Patients presenting with mental retardation were excluded from this study.

2.2. Sample size calculation {#sec2.2}
----------------------------

$$\begin{array}{l}
{\text{n} = \frac{\text{t}^{2} \times \text{p~}\left( {1 - \text{p}} \right)}{\text{m}^{2}}} \\
{= \frac{\left( 1.645 \right)^{2} \times 0.0021\ \left( {1 - 0.0021} \right)}{\left( 0.01 \right)^{2}}} \\
{= \frac{2.706 \times 0.00209559}{0.0001}} \\
{= \ 56.7\text{~∼~}57\text{~samples}} \\
\end{array}$$Where,

n = required sample size

t = confidence level at 90% (standard value is 1.645)

p = estimated prevalence of mucopolysaccharidoses worldwide in percentage (1/48,780 × 100% = 0.0021) [@bib7]

m = margin of error at 1% (0.01)

2.3. Quantitation and characterization of urinary GAGs {#sec2.3}
------------------------------------------------------

MPS urine test includes both quantitative analysis of total GAGs using dimethylmethylene blue method (DMB) and qualitative using High Resolution Electrophoresis (HRE). In brief, 30 μL of standards and patient samples were diluted with 120 μL of deionised water. 825 μL of freshly prepared DMB was later added and mixed thoroughly and analysed by spectrophotometer, at 520 nm. Standard graphs were plotted and used to calculate the value of GAGs in patients' samples. Method is adapted from Nor A [@bib5]. Equal amount of urine is added to cetylpyridinium chloride (CPC) buffer where GAGs in urine is precipitated to form a complex with CPC. The resulting CPC/GAGs complexes are dissociated by addition of lithium chloride and the GAGs re-precipitated with ethanol. The GAGs precipitate was re-dissolved in 20 μL of phenol red. Electrophoresis of the recovered GAGs was undertaken on cellulose acetate using divalent ion buffer system of high ionic strength (0.1 mol/L barium acetate). High resolution was achieved by making use of the different solubility of each GAGs in ethanol/buffer solutions of different concentrations. Interpretation is based upon the quantitative analysis of their relative amounts of excretion and pattern recognition of the specific sulphate(s) detected on HRE.

2.4. Enzyme activity in blood {#sec2.4}
-----------------------------

Enzyme activity was performed in plasma or leukocytes. The leukocytes were extracted from EDTA blood by differential centrifugation as described by van Diggelen et al. (1990). Plasma and leukocyte pellets were kept frozen at −80 °C until analysis. The resulting leukocyte pellet was sonicated in ice for two 5-s bursts at 5 micro/amplitude followed by centrifuged. The supernatants were kept on ice before analysis. Modified Lowry method was used to determine protein concentration. For enzyme assays, methods from Lysosomal Laboratory of Willink Biochemical Genetics, St. Mary\'s Hospital, Manchester, UK were adapted with modification for the assays to be performed in microtiter plates. We used methods described by Hopwood et al. (1979) for MPS Type I [@bib6], MPS II [@bib14], MPS IVA [@bib13], MPS IVB [@bib4], MPS VI [@bib2], and MPS VII [@bib3]. Furthermore, various methods for determination of total β-hexosaminidase [@bib9], β-mannosidase [@bib10] and α-mannosidase [@bib11] for diagnosis of mucolipidoses if all MPS enzyme assay were found normal.

Selected enzyme analysis was performed based on the qualitative results of HRE. Specified volumes of sample (plasma or leukocytes) were mixed with specific buffer and specific artificial substrates were tagged to a fluorescent compound, depending on the enzyme being assayed. The mixtures were incubated at specified times and the reactions were terminated by adding stop buffer. The enzymes in the sample were reacted with the artificial substrate and released the fluorescent compound. This compound was measured using fluorometer. Various concentrations of the fluorescence compound were run as standards and the curves were plotted and used for calculation of product amount. Enzyme activities in plasma were expressed as amount of fluorescent compound (product) being released per ml per hour (nmol/ml/hour). Enzyme activities in leukocytes were expressed as the amount of product being released per ml per mg protein per hour and the unit is nmol/ml/mg protein/hour.
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